Although next-generation sequencing has further helped to define the genetic architecture of MDS allowing for further subdivision of previously uniformly risk-stratified monosomal karyotype patients based on detected mutations such as TP53 [31], monosomy 7 still constitutes a poor-risk cytogenetic subgroup in both the IPSS and the IPSS-R system [2, 6, 7]. This evidence concerns the gene TP53 and myelodysplastic syndrome.